ASX-listed telehealth stocks to look for in August 2021

by Scarlett S. Stock Market Analyst


  • With the COVID-19 pandemic driving increased demand for healthcare and avoiding physical contact, the use of telehealth or telemedicine has expanded rapidly.
  • With customers acknowledging the benefits of telehealth, including convenience and accessibility, experts believe that the trend is here to stay, irrespective of vaccine rollout and the fight against the pandemic.
  • The growing demand for telehealth services has seen companies report impressive financial performance.
  • HeraMed, ResMed, Oneview Healthcare and CardieX are some of the ASX-listed leading players in the telehealth space.

Telemedicine or telehealth companies help people consult with their doctors and other healthcare professionals remotely through phone, message,  or video calls. With the COVID-19 pandemic driving the demand for healthcare services that support social distancing, telehealth is witnessing increased adoption.

Though telehealth services were present before the COVID-19 pandemic, it has only started to pick up in the last 15-19 months. The coronavirus outbreak has triggered the willingness of using telehealth services among the providers and users.

RELATED ARTICLE: COVID-19 may Prove to be Telehealth’s Watershed Moment; Know Why!

Source: Copyright © 2021 Kalkine Media

The significant shift in demand has led to telehealth players reporting impressive financials in their quarterly updates.

This article will talk about four ASX-listed telehealth players whose shares have delivered decent returns in the last three months and have performed consistently.

RELATED ARTICLE: Which are the most exciting telehealth stocks on the ASX?

Let us delve deep and discuss HeraMed, ResMed, Oneview Healthcare and CardieX-

Data Source: ASX, returns calculated as of 3 August 2021


Innovative medical technology player HeraMED is a leader in the digital transformation of maternity care with its hybrid maternity care platform.

On 2 August 2021, HeraMED updated the market that Sheba Medical Centre is expanding its cutting-edge FemTech pilot program to evaluate the HeraBEAT device and HeraCARE platform in women carrying postdate and high-risk pregnancies.  Notably, Sheba Medical Centre is the biggest hospital in Israel and the Middle East.

David Groberman, CEO and Cofounder of HeraMED, stated-

On 29 July 2021, HeraMed updated the market with its Q2 FY21 (three months ending 30 June 2021) results, highlighting that the Company had achieved several important commercialisation milestones during the quarter.

Sponsor Ads

About Scarlett S. Advanced   Stock Market Analyst

37 connections, 0 recommendations, 172 honor points.
Joined APSense since, July 17th, 2019, From Sydney, Australia.

Created on Aug 3rd 2021 07:00. Viewed 273 times.


No comment, be the first to comment.
Please sign in before you comment.